Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
83.91B
Market cap83.91B
Price-Earnings ratio
19.13
Price-Earnings ratio19.13
Dividend yield
0.44%
Dividend yield0.44%
Average volume
840.86K
Average volume840.86K
High today
High today
Low today
Low today
Open price
$806.77
Open price$806.77
Volume
0.00
Volume0.00
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $793.53, giving the company a market capitalization of 83.91B. It carries a P/E multiple of 19.13 and pays a dividend yield of 44.4%.

On 2026-02-18, Regeneron(REGN) shares started trading at $806.77, with intraday highs of — and lows of —.

Trading volume for Regeneron(REGN) stock has reached 0, versus its average volume of 840.86K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

Simply Wall St 1d
Can Regeneron Turn Niche Allergen Antibodies Into a Broader Immunology Growth Engine?

In February 2026, Regeneron Pharmaceuticals announced that 36 abstracts from its immunology and inflammation portfolio were presented at the AAAAI Annual Meetin...

Can Regeneron Turn Niche Allergen Antibodies Into a Broader Immunology Growth Engine?
Simply Wall St 5d
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story

Regeneron Pharmaceuticals is set to present first in class Phase 3 antibody therapy data for cat and birch allergies at the 2026 AAAAI Annual Meeting. The pres...

Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story
TipRanks 5d
Regeneron Advances REGN7508 Into Phase 3 To Tackle Cancer-Linked Blood Clots

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals (REGN) is launching a Phase 3 trial called ROXI...

Analyst ratings

72%

of 29 ratings
Buy
72.4%
Hold
27.6%
Sell
0%

More REGN News

TipRanks 6d
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Sanofi and Regeneron are running a proof-of-concept Phase...

Simply Wall St 7d
A Look At Regeneron Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate

Advertisement What Regeneron’s Recent Trading Says About Investor Focus Regeneron Pharmaceuticals (REGN) has seen mixed share performance recently, with a 3.3...

A Look At Regeneron Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.